Gene Therapy for Multiple Myeloma

(inMMyCAR Trial)

This trial tests a new gene therapy treatment called KLN-1010 for individuals with multiple myeloma, a type of blood cancer that has returned or not responded to other treatments. The primary goal is to assess the safety and tolerability of KLN-1010 and determine the optimal dose for future studies. Candidates who have tried at least three different treatments, including a proteasome inhibitor and immunotherapy, and still have measurable disease might be suitable participants. Those with multiple myeloma meeting these criteria and seeking new options may find this trial of interest. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you require systemic steroids for any condition.

Research has shown that KLN-1010, a new gene therapy for multiple myeloma, is generally safe. Early results suggest that patients tolerate the treatment well. No reports of serious side effects have emerged, which are often a concern with new treatments. Importantly, patients did not experience severe cytokine release syndrome (CRS), a condition that can cause fever and inflammation in some gene therapies. Overall, initial findings indicate KLN-1010 is safe for people, helping it stand out from other similar treatments.¹²³⁴⁵

KLN-1010 is unique because it represents a cutting-edge approach to treating multiple myeloma through gene therapy. Unlike current treatments such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, KLN-1010 works by directly altering the genetic material within cancer cells to stop their growth or even kill them. This new mechanism of action has the potential to target the disease more precisely, minimizing the side effects typically associated with traditional chemotherapy. Researchers are excited because this could lead to more effective and personalized treatment options for patients with multiple myeloma.

Research has shown that KLN-1010, the treatment under study in this trial, holds promise for treating multiple myeloma, a type of cancer. In early studies, all patients showed no detectable cancer cells in their blood after treatment, with this effect lasting up to five months. The treatment employs gene therapy to create special cells in the body that directly attack cancer cells. Additionally, no severe side effects were reported, indicating likely safety. These early results suggest KLN-1010 could effectively treat this cancer.¹²⁴⁶⁷